http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012138043-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
| filingDate | 2011-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012138043-A |
| titleOfInvention | A3AR AGONISTS FOR TREATMENT OF UVEIT |
| abstract | 1. The use of an AAR agonist for the treatment of uveitis in a subject. The use according to claim 1 in a dosage form suitable for oral administration of an AAR agonist to a subject. Use according to claim 2 in a dosage form suitable for oral administration of an AAR agonist twice daily. The use according to claim 1 in a dosage form suitable for topical administration of an AAR agonist to a specified subject. The use of claim 4 in a dosage form suitable for topical administration of an AAR agonist into the eye of a subject. The use according to claim 5, characterized in that the AAR agonist is prepared in the form of eye drops. The use according to any one of claims 1 to 6, characterized in that the AAR agonist is selected from the group consisting of N-2- (4-aminophenyl) ethyladenosine (APNEA), N- (4-amino-3-iodobenzyl) adenosine-5 '- (N-methyluronamide) (AB-MESA), N- (3-iodobenzyl) -adenosine-5'-N-methyluronamide (IB-MECA) and 2-chloro-N- (3-iodobenzyl) adenosine-5' -N-methyluronamide (Cl-IB-MECA) .8. The use of claim 7, wherein the AAR agonist is IB-MECA. 9. A method for treating uveitis, comprising administering to the subject an Adenosine A receptor agonist (AAR) in an amount effective to treat or prevent uveitis. The method of claim 9, wherein the AAR agonist is administered orally. The method of claim 10, wherein the AAR agonist is administered twice daily. The method of claim 9, wherein the AAR agonist is administered locally to said subject. The method of claim 12, wherein the AAR agonist is administered topically to the eye of the subject. The method of claim 13, wherein the AAR agonist is administered into the eye of a subject in the form of eye drops. The method according to any one of claims 9-14, wherein the AAR agonist is selected from the group consisting of N-2- (4-aminophenyl) ethyladenosine (APNEA), N- (4-amino-3-iodobenzyl) adenosine-5 '- (N-methyluron� |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2737157-C2 |
| priorityDate | 2010-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.